沙美特罗/福替卡松对中重度慢阻肺患者稳定期的疗效分析

丁妮娜

（陕西省西安市户县人民医院，陕西 西安，710300）

浏览次数：95次 下载次数：403次

摘要：

目的 探讨沙美特罗/福替卡松对中重度慢阻肺患者稳定期的治疗效果。方法 选择我院2013年8月至2016年8月收治的1 514例稳定期中重度慢阻肺患者为研究对象，随机分为研究组和对照组，各757例。所有患者均给予抗感染、化痰等基础治疗，对照组患者给予氨茶碱进行治疗，在对照组基础上研究组患者给予沙美特罗/福替卡松进行治疗。比较两组患者的生存质量和治疗效果。结果治疗前，两组患者SGRQ 评分比较，差异不显著（P>0.05）；治疗后，两组患者SGRQ 评分均降低，且研究组患者SGRQ 评分显著低于对照组（P<0.05）。研究组患者临床治疗总有效率为96.57%，对照组为87.32%，组间比较， 差异显著（P<0.05）。结论 沙美特罗/福替卡松治疗稳定期慢阻肺患者可明显改善患者生活质量，提高治疗效果，可推广使用。

关键词：中重度慢肺阻；沙美特罗/福替卡松；氨茶碱；稳定期

中图分类号：R563.9文献标志码：A文章编号：2096-1413(2017)33-0036-02

Curative effect analysis of salmeterol /fluticasone in patients with moderate and severe chronic obstructive pulmonary

disease in stable phase
DING Ni-na
(Hu County People``s Hospital, Xi``an 710300, China)

ABSTRACT: Objective To investigate the treatment effect of salmeterol /fluticasone in patients with moderate and severe chronic obstructive pulmonary disease in stable phase. Methods In our hospital from August 2013 to August 2016, 1 514 patients with moderate and severe chronic obstructive pulmonary disease in stable phase were selected as the research objects, which were randomly divided into research group and control group, with 757 cases in each group. All patients were treated with anti -infection, expectorant and other basic treatment, patients in the control group received aminophylline, based on the control group, the patients in the research group were given salmeterol / fluticasone. The quality of life and treatment effects were compared between the two groups. Results There was no significant difference in the SGRQ score between the two groups before treatment (P>0.05); after treatment, the SGRQ scores decreased in the two groups, and the SGRQ score of the patients in the research group was significantly lower than that in the control group (P<0.05). The clinical total effective rate was 96.57% in the research group and 87.32% in the control group, the difference between the two groups was statistically significant (P<0.05). Conclusion Salmeterol / fluticasone in the treatment of moderate and severe chronic obstructive pulmonary disease in stable phase can significantly improve the quality of life of patients and improve the therapeutic effect, which can be widely used.
KEYWORDS: moderate and severe chronic obstructive pulmonary disease; salmeterol / fluticasone; aminophylline; stable phase

参考文献：
[1] 刘燕,晋小祥,金邦贤.沙美特罗/福替卡松对中重度慢阻肺患者稳 定期临床疗效的观察[J].安徽医药,2013,17(1):120-122.
[2] 徐鸿.沙美特罗/福替卡松对中重度慢性阻塞性肺疾病患者稳定 期的临床疗效观察[J].中国医药指南,2013,11(23):622-623.
[3] ANTHONY D,DONOHUE J F,PETER K,et al.A re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary disease[J].Expert Opin Pharmacother,2015,16 (12):1845-1860.
[4] 朱时宝.联用噻托溴铵和沙美特罗替卡松治疗慢阻肺的效果分析 [J].当代医药论丛,2016,14(18):65-66.
[5] 古辉,徐小彭,钟获华.沙美特罗/福替卡松对中重度慢阻肺患者稳 定期的疗效观察[J].北华大学学报:自然科学版,2014,15(2):225-228.
[6] 张芳兰,王艳娟,王莉珺,等.评价沙美特罗替卡松治疗稳定型慢阻 肺的临床效果观察[J].中国保健营养,2016,26(21):281-282.
[7] 戴斌,杨颖乔,徐旭燕.沙美特罗联合福替卡松对中重度COPD 的 疗效观察及安全性分析[J].湖北科技学院学报:医学版,2016,30(3):210-212.
[8] 郁震,曹娟,王红梅,等.噻托溴铵联合沙美特罗替卡松对慢阻肺急 性加重期患者免疫功能的影响[J].临床肺科杂志,2016,21(5):795-798.
[9] 刘杨,薛华.沙美特罗替卡松气雾剂治疗稳定期慢性阻塞性肺疾病 的临床研究[J].中国继续医学教育,2016,8(6):139-140.